FDA Approves FoundationOne Tests for Olaparib Combo in BRCA-Mutated mCRPC
The FDA approved FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for olaparib plus abiraterone and prednisone in patients with BRCA-mutated metastatic CRPC, following the 2023 approval of this combination therapy based on the PROpel trial results.
Related Clinical Trials
Reference News
The FDA approved FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for olaparib plus abiraterone and prednisone in patients with BRCA-mutated metastatic CRPC, following the 2023 approval of this combination therapy based on the PROpel trial results.
FDA approves FoundationOne® CDx and FoundationOne Liquid CDx as companion diagnostics for olaparib plus abiraterone acetate and prednisone or prednisolone in BRCA-mutated mCRPC, based on PROpel trial data showing improved radiological progression-free survival and overall survival in BRCA-mutated patients.